Zusammenfassung
Ist Ihr Patient über 50 Jahre alt? Dann sollten Sie ihn nach Symptomen einer Prostatavergrößerung fragen. Wenn er über einen schwachen Harnstrahl, Harndrang und Nykturie berichtet, müssen Sie hellhörig werden. Informieren Sie sich hier über die notwendigen diagnostischen Schritte und die therapeutischen Möglichkeiten.
Literatur
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol [Internet] 1984 Sep [cited 2014 Mar 26];132(3):474–479; available from: http://www.ncbi.nlm.nih.gov/pubmed/6206240
Handzel DM, Briesen S, Rausch S, Kälble T. Cataract surgery in patients taking alpha-1 antagonists: know the risks, avoid the complications. Dtsch Arztebl Int [Internet] 2012 May [cited 2012 Jul 18];109(21):379–384; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3371631&tool=pmcentrez&rendertype=abstract
Steers WD. 5alpha-reductase activity in the prostate. Urology [Internet] 2001 Dec [cited 2014 Mar 26];58(6 Suppl 1):17–24; discussion 24; available from: http://www.ncbi.nlm.nih.gov/pubmed/11750244
Gravas S, Bachmann A, Descazeaud A, Drake M, Gratzke C, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KA. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Uroweb 2014; available at: http://www.uroweb.org/guidelines/online-guidelines/?no_cache=1, accessed May 20, 2014
Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med [Internet] 1995 Jan 12 [cited 2014 Mar 26];332(2):75–79; available from: http://www.ncbi.nlm.nih.gov/pubmed/7527493
Netto NR, de Lima ML, Netto MR, D'Ancona CA. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. Urology [Internet] 1999 Feb [cited 2014 Mar 26];53(2):314–316; available from: http://www.ncbi.nlm.nih.gov/pubmed/9933046
Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology [Internet] 2008 Jan [cited 2014 Mar 26];82(4):270–275; available from: http://www.ncbi.nlm.nih.gov/pubmed/18849646
Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis [Internet] 2004 Jan [cited 2014 Mar 26];7(3):195–200; available from: http://www.ncbi.nlm.nih.gov/pubmed/15289814
Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane database Syst Rev [Internet] 2000 Jan [cited 2014 Mar 26];(2):CD001043; available from: http://www.ncbi.nlm.nih.gov/pubmed/10796740
Schulz V, Hänsel R. Rationale Phytotherapie [Internet] Berlin, Heidelberg: Springer Berlin Heidelberg; 2004 [cited 2014 Mar 26]; available from: http://www.springerlink.com/index/10.1007/978-3-642-18842-8
Wilt T, Ishani A, MacDonald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(1): CD001044. http://www.ncbi.nlm.nih.gov/pubmed/11869585
Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane database Syst Rev [Internet] 2000 Jan [cited 2014 Mar 26];(2):CD001042; available from: http://www.ncbi.nlm.nih.gov/pubmed/10796739
Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane database Syst Rev [Internet] 2012 Jan [cited 2014 Mar 26];12:CD001423; available from: http://www.ncbi.nlm.nih.gov/pubmed/23235581
Kortmann BBM, Floratos DL, Kiemeney LALM, Wijkstra H, de la Rosette JJMCH. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology [Internet] 2003 Jul [cited 2014 Mar 26];62(1):1–9; available from: http://www.ncbi.nlm.nih.gov/pubmed/12837408
Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate [Internet] 1997 Sep 15 [cited 2014 Mar 26];33(1):55–59; available from: http://www.ncbi.nlm.nih.gov/pubmed/9294627
Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract [Internet] 2008 Oct [cited 2014 Mar 26];62(10):1547–1559; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2658011&tool=pmcentrez&rendertype=abstract
Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology [Internet] 2004 Dec [cited 2014 Mar 26];64(6):1081–1088; available from: http://www.ncbi.nlm.nih.gov/pubmed/15596173
Handzel DM, Rausch S, Kälble T, Briesen S. [Managing complications in intraoperative floppy iris syndrome.] Ophthalmologe [Internet] 2013 Jan 23 [cited 2013 Jan 27]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23338529
Andriole G, Bruchovsky N, Chung LWK, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol [Internet] 2004 Oct [cited 2014 Mar 26];172(4 Pt 1):1399–1403; available from: http://www.ncbi.nlm.nih.gov/pubmed/15371854
Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther [Internet] 2007 Jan [cited 2014 Mar 26];29(1):17–25; available from: http://www.ncbi.nlm.nih.gov/pubmed/17379044
Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology [Internet] 1996 Sep [cited 2014 Mar 26];48(3):398–405; available from: http://www.ncbi.nlm.nih.gov/pubmed/8804493
Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int [Internet] 2005 Sep [cited 2014 Mar 26];96(4):572–577; available from: http://www.ncbi.nlm.nih.gov/pubmed/16104912
Gittelman M, Ramsdell J, Young J, McNicholas T. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. J Urol [Internet] 2006 Sep [cited 2014 Mar 26];176(3):1045–1050; discussion 1050; available from: http://www.ncbi.nlm.nih.gov/pubmed/16890688
Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med [Internet] 1996 Aug 22 [cited 2014 Mar 26];335(8):533–539; available from: http://www.ncbi.nlm.nih.gov/pubmed/8684407
Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology [Internet] 2003 Jan [cited 2014 Mar 26];61(1):119–126; available from: http://www.ncbi.nlm.nih.gov/pubmed/12559281
Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT stu. Eur Urol [Internet] 2009 Feb [cited 2014 Mar 26];55(2):461–471; available from: http://www.ncbi.nlm.nih.gov/pubmed/19013011
Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol [Internet] 2008 Dec [cited 2014 Mar 26];26(6):603-609; available from: http://www.ncbi.nlm.nih.gov/pubmed/18607596
Uckert S, Oelke M, Stief CG, Andersson K-E, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol [Internet] 2006 Apr [cited 2014 Mar 26];49(4):740–745; available from: http://www.ncbi.nlm.nih.gov/pubmed/16460876
Uckert S, Küthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol [Internet] 2001 Dec [cited 2014 Mar 26];166(6):2484–2490; available from: http://www.ncbi.nlm.nih.gov/pubmed/11696815
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol [Internet] 2008 Feb [cited 2014 Mar 27];179(2):616–621; discussion 621; available from: http://www.ncbi.nlm.nih.gov/pubmed/18082216
Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive detrusor. BJU Int 2004 Oct;94(6):817–820; http://www.ncbi.nlm.nih.gov/pubmed/15476515
Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009 Dec;182(6):2825–2833; http://www.ncbi.nlm.nih.gov/pubmed/19837435
Athanasopoulols A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an a-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized,controlled study. J Urol 2003 Jun;169(6):2253–2256
Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol 2009;56:534–543
Arenas da Silva LF, Schönthaler M, Cruz F, Gratzke C, Zumbe J, Stenzl A, Amend B, Sievert KD. [New treatment strategies for male lower urinary tract symptoms] Urologe A 2012 Dec;51(12):1697–1702. doi: 10.1007/s00120-012-3032-1. German. PMID: 23139025 [PubMed - indexed for MEDLINE]
McNicholas TA, Woo HH, Chin PT, Bolton D, Fernández Arjona M, Sievert KD, Schoenthaler M, Wetterauer U, Vrijhof EJ, Gange S, Montorsi F. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 2013 Aug;64(2): 292–299; doi: 10.1016/j.eururo.2013.01.008. Epub 2013 Jan 19. PMID: 23357348 [PubMed - indexed for MEDLINE]
Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, Chin PT, Woo HH. Multicentre prospective crossover study of the xxx201A;prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014 Apr;113(4):615–622; doi: 10.1111/bju.12540. PubMed PMID: 24765680
Marchal C, Perez JE, Herrera B et al. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn 2012 Jan; 31(1):86–92
Chuang YC, Huang CC, Kang HY et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006 Mar;175(3 Pt 1):1158–1163
Brisinda G, Cadeddu F, Vanella S et al. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009 Jan;73(1):90–94
Varkarakis J, Bartsch G, Horninger W. Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up. Prostate [Internet] 2004 Feb 15 [cited 2014 Mar 27];58(3):248–251; available from: http://www.ncbi.nlm.nih.gov/pubmed/14743463
Yang Q, Peters TJ, Donovan JL, Wilt TJ, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol [Internet] 2001 May [cited 2014 Mar 27];165(5):1526–1532; available from: http://www.ncbi.nlm.nih.gov/pubmed/11342911
Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med [Internet] 1989 Apr 27 [cited 2014 Mar 27];320(17): 1120–1124; available from: http://www.ncbi.nlm.nih.gov/pubmed/2469015
Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol [Internet] 2006 Nov [cited 2014 Mar 27];50(5):969–979; discussion 980; available from: http://www.ncbi.nlm.nih.gov/pubmed/16469429
Rassweiler J, Schulze M, Stock C, Teber D, De La Rosette J. Bipolar transurethral resection of the prostate - technical modifications and early clinical experience. Minim Invasive Ther Allied Technol [Internet] 2007 Jan [cited 2014 Mar 27];16(1):11-21; available from: http://www.ncbi.nlm.nih.gov/pubmed/17365673
Bachmann A, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, Grimm MO, Benejam J, Stolzenburg JU, Riddick A, Pahernik S, Roelink H, Ameye F, Saussine C, Bruyère F, Loidl W, Larner T, Gogoi NK, Hindley R, Muschter R, Thorpe A, Shrotri N, Graham S, Hamann M, Miller K, Schostak M, Capitán C, Knispel H, Thomas JA. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial - the GOLIATH study. Eur Urol 2014 May;65(5):931–942; doi: 10.1016/j.eururo.2013.10.040. Epub 2013 Nov 11. PubMed PMID: 24331152.
Le Duc A, Gilling PJ. Holmium laser resection of the prostate. Eur Urol [Internet] 1999 Feb [cited 2014 Mar 27];35(2):155–160; available from: http://www.ncbi.nlm.nih.gov/pubmed/9933809
Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg [Internet] 2007 Oct [cited 2014 Mar 27];94(10):1201–1208; available from: http://www.ncbi.nlm.nih.gov/pubmed/17729384
Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G, et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ [Internet] 2008 Jan [cited 2014 Mar 27];337:a449; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2443595&tool=pmcentrez&rendertype=abstract
Kabalin JN, Mackey MJ, Cresswell MD, Fraundorfer MR, Gilling PJ. Holmium: YAG laser resection of prostate (HoLRP) for patients in urinary retention. J Endourol [Internet] 1997 Aug [cited 2014 Mar 27];11(4):291–293; available from: http://www.ncbi.nlm.nih.gov/pubmed/9376851
Rieken M, Bachmann A, Gratzke C. Laservaporization of the prostate: current status of the greenlight and diode laser. Urologe A [Internet] 2013 Mar [cited 2014 Mar 30];52(3):339–344; available from: http://www.ncbi.nlm.nih.gov/pubmed/23429879
Chung DE, Wysock JS, Lee RK, Melamed SR, Kaplan SA, Te AE. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol [Internet] 2011 Sep [cited 2014 Mar 30];186(3):977–981; available from: http://www.ncbi.nlm.nih.gov/pubmed/21791350
Naspro R, Suardi N, Salonia A, Scattoni V, Guazzoni G, Colombo R, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates > 70 g: 24-month follow-up. Eur Urol [Internet] 2006 Sep [cited 2014 Mar 27];50(3):563–568; available from: http://www.ncbi.nlm.nih.gov/pubmed/16713070
Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivizatos G. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol [Internet] 2008 Oct [cited 2014 Mar 27];22(10):2333–2340; available from: http://www.ncbi.nlm.nih.gov/pubmed/18837655
Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol [Internet] 2008 Jan [cited 2014 Mar 27];53(1):160–166; available from: http://www.ncbi.nlm.nih.gov/pubmed/17869409
Gratzke C, Schlenker B, Seitz M, Karl A, Hermanek P, Lack N, et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol [Internet] 2007 Apr [cited 2014 Mar 27];177(4):1419–1422; available from: http://www.ncbi.nlm.nih.gov/pubmed/17382744
Gravas S (chair), Bachmann A, Descazeaud A, Drake M, Gratzke C, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benigin prostatic obstruction (BPO), http://www.uroweb.org/guidelines/online-guidelines/, ISBN 978-90-79754-65-6
Author information
Authors and Affiliations
Corresponding author
Additional information
Interessenkonflikt
Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Herr Dr. Rausch legt folgende potenzielle Interessenkonflikte offen: keine. Herr Prof. Sievert: Neotract (Urolift®) Investigator BPH6-Study.
Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.
This article is part of a supplement not sponsored by the industry.
Rights and permissions
About this article
Cite this article
Rausch, S., Sievert, KD. Machen Sie aus dem Träufeln wieder einen Fluss!. MMW - Fortschritte der Medizin 156 (Suppl 6), 78–85 (2014). https://doi.org/10.1007/s15006-014-3297-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-014-3297-y